Abbott has launched its Proclaim dorsal root ganglion neurostimulation system in Europe for patients suffering from chronic neuropathic pain.
The new Proclaim DRG Neurostimulation System targets sensory nerves packed within the dorsal root ganglion to directly target the area of the body where pain occurs.
It offers stronger pain relief compared to traditional spinal cord stimulation therapy.
Featuring platform's Bluetooth wireless technology and iOS software, the system will deliver DRG stimulation for the treatment of chronic neuropathic pain.
It also uses an iPod touch mobile digital device patient controller, which offers wireless communication through Bluetooth wireless technology.
Proclaim DRG neurostimulation system is said to target nerves within the DRG, a spinal structure packed with sensory nerves.
The system enables physicians to treat chronic pain in specific areas of the upper and lower body, such as the foot, knee, hip or groin.
According to the company, DRG stimulation has been clinically demonstrated to offer better pain relief over traditional spinal cord stimulation (SCS) therapy by directly targeting the area of the body where pain occurs.
Abbott neuromodulation medical director Dr Allen Burton said: "Abbott continues to pursue innovative solutions for chronic pain because far too many patients with chronic intractable pain battle symptoms that are not adequately managed with current therapies.
"Our Proclaim DRG Neurostimulation System addresses this unmet need by offering a therapy that is superior to traditional spinal cord stimulation combined with patient-friendly technology."
Abbot produces radiofrequency ablation (RFA) and SCS therapy solutions, including BurstDR stimulation and stimulation of the DRG to treat chronic pain.
Image: Abbott’s global headquarters in Illinois. Photo: courtesy of Abbott.